Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies

Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells

Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies

Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function

Myeloid-derived suppressor cells in glioma

Dendritic cell-based immunotherapy in ovarian cancer

Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials

Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma

Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host